We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cyprotex Adds Service to Support Early Drug Discovery

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Cyprotex has announced the launch of a service to help drug discovery groups to assess new oral drug candidates.

The service, known as Cloe Screen PAMPA (Parallel Artificial Membrane Permeation Assay) complements Cyprotex's existing portfolio of compound screens for evaluating the permeability of drug discovery compounds.

Cloe Screen PAMPA is designed to provide a way to prioritise compounds based on their potential to cross the gut wall and it is based on assessing simple permeability properties.

It enables drug researchers to see how their compounds behave in the different pH environments that exist throughout the entire gastro-intestinal tract. 

Cloe Screen PAMPA uses mass spectrometry (LC-MS/MS) as an end-point to ensure greater data accuracy and sensitivity than traditionally employed absorbance measurements.

Commenting on the launch of this new service, Dr. Darwin Cheney, Cyprotex's Chief Scientific Officer, said, "The Cloe Screen PAMPA offers our partners a high quality, fast turnaround assay that displays notable reproducibility."

"In addition, we have demonstrated that our assay shows several fold improvement in sensitivity over currently available PAMPA assays."